Fullpower Technologies, in collaboration with Stanford Sleep Medicine and UCSF Department of Psychiatry and Behavioral Sciences, has officially presented two new studies at the SLEEP 2024 conference to build upon our understanding of sleep fragmentation and heart rate variability (HRV) during sleep. According to certain reports, the first study, which was led by Dr. Clete Kushida from Stanford University, investigated sleep fragmentation across different age groups and genders using Fullpower’s Sleeptracker-AI® data from over 117,000 participants and over 10 million recorded nights. Once the analysis was done, we markedly got to know that men showcased significantly higher sleep fragmentation during REM sleep compared to women across all ages above 24. Having said so, this fragmentation would drop after the age of 34. Almost like an extension of that, the first study uncovered age-related differences on a wider scale, considering we learnt how sleep fragmentation increased with age during NREM sleep for both genders but showed a complex pattern during REM sleep, initially increasing up to 25-34 years and then decreasing gradually with age.
The second study, which was led by, Dr. Yue Leng from the University of California, San Francisco, had its primary focus rooted in examining HRV in over 38,000 individuals. Using Fullpower’s Sleeptracker-AI® Monitor, this particular study collected HRV data from 2.7 million recorded nights so to properly gauge the impact of obstructive sleep apnea (OSA). Going by what we saw here, the findings revealed that individuals with moderate to severe OSA had significantly higher overall HRV variability (SDNN) and lower parasympathetic activity (RMSSD) than those without OSA. These differences were even more pronounced in middle-aged adults. Another thing the second study would go on to reveal were the age and gender-related differences. You see, both HRV metrics decreased with age. Furthermore, SDNN was consistently lower in females, while RMSSD showed greater reductions in individuals with severe OSA, particularly among younger and middle-aged adults.
“We are proud of our continued collaboration in advancing Sleep Science research with Stanford Sleep Medicine and UCSF. Together, we are sharing these new findings with the sleep research community leveraging the Sleeptracker.ai platform and network of sleepers,” said Philippe Kahn, CEO of Fullpower.ai.
Founded in 2005, Fullpower.ai’s rise stems from its generative AI biosensing platform, which is currently vetted and deployed in more than 60 different countries. As of today, the stated platform has well over 100,000 biosensing connected AI-powered OTC devices, along with more than 15,000 biosensing-connected AI-powered FDA devices. Boasting 135+ patents, Fullpower.ai’s clientele currently stretches across wide spectrum, ranging from sleep and life sciences companies to health, wellness, and biotechnology players.
